Qiagen (QGEN) shares jump on takeover talk as PE firms and a US molecular testing buyer eye a deal at a “realistic premium.” ...

Qiagen (NYSE:QGEN) just received U.S. FDA clearance for its QIAstat-Dx gram-negative bloodstream infection panel, giving ...

QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.

Qiagen (ISIN NL0015002SN0) stock traded at USD 45.2920 on the NYSE on October 2, 2026, up 7.7 percent from the prior close.

Qiagen (NYSE:QGEN) shares gained 4% on Thursday morning following a media report that several private equity firms are considering potential offers for the molecular testing company. German ...

Qiagen recorded 2025 sales of $2.09 billion, up 5% at constant exchange rates. (Getty Images/Overearth) Qiagen’s outgoing chief executive Thierry Bernard, M.D., told investors the company does not ...

Qiagen stock was at EUR 39.86 after-hours at 7:45 p.m. CEST on October 2, 2026. The price was up plus 6.26 percent versus the ...

QIAGEN N.V.QGEN is well positioned for growth in the upcoming quarters, supported by continued test menu expansion. Meanwhile ...

QIAGEN N.V. has reported a notification from the Netherlands Authority for the Financial Markets indicating that Bank of America Corporation has built a substantial position in the company. The filing ...

Shareholders will be asked to vote on the appointment of Jonathan M. Pratt to the QIAGEN Managing Board after he joined QIAGEN as Chief Executive Officer on September 1, 2026. Subject to shareholder ...

Fully automated workflow targeted for late 2027 launch integrates QuantiFERON test, Diasorin LIAISON systems, and purpose-built end-to-end automation from new Inpeco partnership AI-enabled risk ...

Venlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an important milestone with the launch of 100 new assays for its digital ...